Patents Examined by Maher M. Haddad
  • Patent number: 11185585
    Abstract: Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: November 30, 2021
    Assignee: The Regents of the University of California
    Inventors: Warren Shawn Carbonell, Manish Kumar Aghi
  • Patent number: 11174309
    Abstract: An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: November 16, 2021
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Kyung Eun Kim, Seung Ja Oh, Hyo Seon Lee, Sang Yeul Han
  • Patent number: 11155613
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: October 26, 2021
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Jae-Keun Lee, Dong Sik Kim
  • Patent number: 11142576
    Abstract: The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin ?1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: October 12, 2021
    Assignee: Oncosynergy, Inc.
    Inventor: W. Shawn Carbonell
  • Patent number: 11142579
    Abstract: The present disclosure provides variant anti-OX40 antibodies that mimic the activity of OX40L by behaving as an agonist against receptor OX40 to enhance T cell clonal expansion and differentiation. The variant anti-OX40 antibodies exhibit improved binding affinity for OX40 and improved agnostic activity, compared to a wild type anti-OX40 antibody (wild type 2B4 clone) from which the variant clones are derived. The variant anti-OX40 antibodies specifically bind OX40 receptors on activated T lymphocytes, stimulate proliferation of effector T cells, stimulate proliferation of effector T cells in the presence of regulatory T cells, and stimulate production of at least one cytokine from effector T cells.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: October 12, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventor: Min Soo Kim
  • Patent number: 11136412
    Abstract: Disclosed is an antibody which binds to a symmetrically dimethylated arginine analyte that can be used to detect a symmetrically dimethylated arginine analyte in a sample, such as in a homogeneous enzyme immunoassay method.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: October 5, 2021
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Valdez, Byung Sook Moon, Ki Chung, Yunfei Chen
  • Patent number: 11117962
    Abstract: The present invention provides an antibody to a fibrosis-related molecule and medical application thereof. The antibody of the present invention is an antibody that binds to CHL1 protein and an antibody that neutralizes the binding of the CHL1 protein to a fibroblast.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: September 14, 2021
    Assignee: The University of Tokyo
    Inventors: Yosuke Kurashima, Hiroshi Kiyono
  • Patent number: 11104728
    Abstract: The present invention relates to an anti-EMAP II antibody or an antigen-binding fragment thereof, a nucleic acid molecule for coding the same, or a preparation method thereof. Also, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in preventing, treating or diagnosing EMAP II-mediated diseases, for example, TNF-?-mediated disease or Alzheimer's disease. Furthermore, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in detecting or quantifying an EMAP II antigen. The antibody of the present invention may exhibit a more improved antigen-binding capacity compared to existing anti-EMAP antibodies and may treat the TNF-?-mediated disease more effectively.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: August 31, 2021
    Assignee: HUB Biotech Co., Ltd.
    Inventors: Sang Gyu Park, Gook-Jin Kang
  • Patent number: 11096998
    Abstract: BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: August 24, 2021
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Chen Ni Chin, John Lee, Timothy McCabe, Jill Mooney, Michael Naso, William Strohl
  • Patent number: 11091551
    Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: August 17, 2021
    Assignee: Genentech, Inc.
    Inventors: Mary Keir, Gaik Wei Tew
  • Patent number: 11091558
    Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human OX40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-OX40 antibody of the invention.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: August 17, 2021
    Assignee: BEIJING MABWORKS BIOTECH CO. LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Lun Jiang, Feng Li
  • Patent number: 11081235
    Abstract: The invention provides isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within said peptides. Pharmaceutical compositions comprising said peptides and antibodies are also disclosed as well as methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: August 3, 2021
    Assignees: MOR-RESEARCH APPLICATIONS LTD., TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.
    Inventors: Michal A. Rahat, Nitza Lahat, Miriam Walter, Haim Bitterman
  • Patent number: 11072661
    Abstract: Disclosed are agents inhibiting the interaction between CFH and CD11b/18, as well as the use of such agents, in particular for treating inflammatory disorders, such as age-related macular degeneration.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: July 27, 2021
    Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Florian Sennlaub, Bertrand Callippe, Xavier Guillonneau, José-Alain Sahel
  • Patent number: 11066473
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: July 20, 2021
    Assignees: argenx IIP BV, VIB VZW, Universiteit Gent
    Inventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • Patent number: 11046756
    Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: June 29, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Yanbin Liang, Daniel W. Gil
  • Patent number: 11041019
    Abstract: The present invention relates to an isolated specific binding molecule which binds human Anx-A1 and comprises the complementarity-determining regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, wherein each of said CDRs has an amino acid sequence as follows: VLCDR1 has the sequence set forth in SEQ ID NO: 1, 36 or 37; VLCDR2 has the sequence set forth in SEQ ID NO: 2; VLCDR3 has the sequence set forth in SEQ ID NO: 3; VHCDR1 has the sequence set forth in SEQ ID NO: 4; VHCDR2 has the sequence set forth in SEQ ID NO: 5; and VHCDR3 has the sequence set forth in SEQ ID NO: 6; or, for each sequence, an amino acid sequence with at least 85% sequence identity thereto. The specific binding molecule disclosed is therapeutically useful and in particular may be used in therapy for T-cell mediated diseases, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, obsessive compulsive disorder (OCD), and OCD-related diseases, such as anxiety disorders.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: June 22, 2021
    Assignee: MEDANNEX LTD.
    Inventors: Henry Charles Wilson Hays, Christopher Barry Wood, Tina Caroline Flatau
  • Patent number: 11014985
    Abstract: Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 25, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jie Liu, Irving L. Weissman, Ravindra Majeti
  • Patent number: 11008384
    Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 18, 2021
    Assignee: STERLING IP LIMITED
    Inventors: Kim Suzanne Midwood, Philip Antony Bland-Ward, Nigel Burns, Patrick John Hextall, Susan Rebecca Aungier
  • Patent number: 10994009
    Abstract: A method of treating pulmonary metastasis of osteosarcoma cells (pOSs) in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that interferes with VCAM-1/?4?1 signaling between pOSs expressing VCAM-1 and pulmonary macrophages (MACs) expressing ?4?1.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: May 4, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Alex Yee-Chen Huang, Jay T. Myers
  • Patent number: 10994010
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: May 4, 2021
    Assignees: UNIVERSITAETSKLINIKUM FREIBURG, BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD.
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter